References
- Biswas M , VanwongN , SukasemC. Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder. Pharmacogenomics23(8), 493–503 (2022).
- Mostafa S , PolasekTM , BousmanCAet al. Pharmacogenomics in psychiatry – the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing. Pharmacogenomics23(15), 857–867 (2022).
- Chan ER , MehlotraRK , PiraniKA. CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study. Pharmacogenomics23(5), 315–325 (2022).
- Krause DS , DowdD. Use of a consultation service following pharmacogenetic testing in psychiatry. Pharmacogenomics23(5), 327–333 (2022).
- Roosan D . The promise of digital health in healthcare equity and medication adherence in the disadvantaged dementia population. Pharmacogenomics23(9), 505–508 (2022).
- Roosan D , ChokJ , BaskysA , RoosanMR. PGxKnow: a pharmacogenomics educational HoloLens application of augmented reality and artificial intelligence. Pharmacogenomics23(4), 235–245 (2022).
- Biswas M , SukasemC , KaliMSK , IbrahimB. Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Pharmacogenomics23(3), 207–222 (2022).
- Galli M , Ortega-PazL , FranchiF , RolliniF , AngiolilloDJ. Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. Pharmacogenomics23(13), 723–737 (2022).
- Cicali EJ , WiisanenK. The importance of phenoconversion when using the CYP2D6 genotype in clinical practice. Pharmacogenomics23(14), 749–752 (2022).
- Booyse RP , TwesigomweD , HazelhurstS. Characterization of POR haplotype distribution in African populations and comparison with other global populations. Pharmacogenomics23(14), 771–782 (2022).